BFM
HZNP

Boothbay Fund Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Boothbay Fund Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-69,600
Closed -$7.92M – 2733
2022
Q4 		$7.92M Sell
69,600
-17,400
-20% -$1.45M 0.18% 95
2022
Q3 		$5.38M Buy
+87,000
New +$6.08M 0.13% 165
2022
Q2 		– Sell
-33,300
Closed -$3.5M – 2935
2022
Q1 		$3.5M Buy
33,300
+23,200
+230% +$2.26M 0.08% 335
2021
Q4 		$1.09M Buy
+10,100
New +$1.1M 0.03% 711
2021
Q1 		– Sell
-277
Closed -$2.03M – 2015
2020
Q4 		$2.03M Buy
+277
New +$20.6K 0.08% 263

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Boothbay Fund Management's HZNP Position: Q4 2023 in Review

Boothbay Fund Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 69,911 shares — an estimated $8.09M sold.

Boothbay Fund Management first reported a position in HZNP in Q4 2018 and held it in 14 quarters. The position peaked at $10.5M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Boothbay Fund Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 69,911 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $8.09M.
  • Boothbay Fund Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 14 quarters.
  • Boothbay Fund Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $10.5M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Boothbay Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.